Efficacy and safety of a reduced starting dose of cabozantinib (20 mg) plus nivolumab for renal cell carcinoma in real-world practice
A 20-mg starting dose of cabozantinib in C + N therapy can achieve almost the same efficacy as a normal starting dose for patients who are hesitant to start treatment at the normal 40-mg dose.
Authors
- Tomokazu Sazuka (ORCID: https://orcid.org/0000-0002-8902-7853)
- Sangjon Pae
- Yusuke Imamura (ORCID: https://orcid.org/0009-0006-7207-1520)
- Kohei Nagaoka
- Yasutaka Yamada (ORCID: https://orcid.org/0000-0002-0070-1590)
- Fusako Yokochi (ORCID: https://orcid.org/0000-0003-3890-1667)
- Keisuke Ando
- Kodai Sato (ORCID: https://orcid.org/0000-0001-6914-4991)
- Shinichi Sakamoto
- Shinpei Saito (ORCID: https://orcid.org/0000-0002-9346-0553)
- Yuri Watanabe
- K. Toma
- Y. Onoda
Institutions
- Chiba University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1093/jjco/hyaf135
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00